Amgen

2023 Marks Robust Investment in Montgomery County, Maryland

Retrieved on: 
Wednesday, January 24, 2024
Xchange, Silicon, Economic development, Patient, Amgen, Therapy, Honest Tea, NIST, Cancer, County, Food, Investment, Acquisition, Horizon Therapeutics, NIH, Change, FDA, Workforce, Bangladesh Technical Education Board, Growth, Food delivery

ROCKVILLE, Md., Jan. 24, 2024 /PRNewswire/ -- Montgomery County, Maryland, companies had a strong year of investment in 2023, with more than $2.2 billion generated through more than 100 deals. Companies in a wide range of industries, from life sciences and technology to manufacturing and real estate, brought in substantial investments showcasing a positive economic direction going into 2024.

Key Points: 
  • Montgomery County, MD, companies had a strong year of investment in 2023, with more than $2.2 billion generated.
  • Life sciences companies in Montgomery County continue to be a powerful driver of investment, with more than $500 million dollars generated in 2023.
  • "The robust investment in Montgomery County companies is a testament to our pioneering spirit, diversity, and exceptional climate for business growth," said Bill Tompkins, president and CEO of Montgomery County Economic Development Corporation.
  • To learn more about doing business in Montgomery County, Maryland, go to thinkmoco.com or the Montgomery County Business Center .

Tickets and Sponsorships Available for the 2024 Prevent Blindness Person of Vision Award Gala During Vision Expo East, Honoring Ed Buffington, GPN Technologies

Retrieved on: 
Monday, January 22, 2024
Bausch & Lomb, Amgen, CooperVision, Platinum, VSP Vision Care, Regeneron Pharmaceuticals, Vision Source, Person, VSP, The Vision Council, Publication, IDOC, Nightcap, Visual impairment, Fashion design

CHICAGO, Jan. 22, 2024 /PRNewswire-PRWeb/ -- Tickets and sponsorships are still available for the 2024 Prevent Blindness Person of Vision Award, honoring Ed Buffington, president and CEO of GPN Technologies. Prevent Blindness will also be giving special recognition to 20/20 Magazine in celebration of its 50th Anniversary of publication during the event. The Person of Vision Award gala will be held on March 14, 2024, at 583 Park Avenue, New York City, in conjunction with Vision Expo East.

Key Points: 
  • Prevent Blindness Annual Fundraising "Person of Vision Award" Gala to Honor Ed Buffington, GPN Technologies, and Give Special Commemoration of 20/20 Magazine for its 50 Years of Publication
    CHICAGO, Jan. 22, 2024 /PRNewswire-PRWeb/ -- Tickets and sponsorships are still available for the 2024 Prevent Blindness Person of Vision Award , honoring Ed Buffington, president and CEO of GPN Technologies .
  • The Person of Vision Award gala will be held on March 14, 2024, at 583 Park Avenue , New York City, in conjunction with Vision Expo East .
  • The Prevent Blindness Person of Vision Award recognizes an individual, corporation and/or organization whose inspired outlook champions healthy vision and its importance for a healthy life.
  • For more information on the 2024 Prevent Blindness Person of Vision Gala, including tickets and sponsorship opportunities, please contact Albert Muci at (312) 363-6020 or [email protected] , or visit https://preventblindness.org/personofvision .

GeminiBio Appoints Steven Sandoval, Sr. to its Board of Directors

Retrieved on: 
Thursday, January 18, 2024
Amgen, Gene, Cell, Engineering, Biotechnology, Fine chemical

FORT LAUDERDALE, Fla. and WEST SACRAMENTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Steven Sandoval, Sr., to its Board of Directors.

Key Points: 
  • Mr. Sandoval is the CEO of Pharmaceutical Technical Solutions, Inc., an engineering and pharma manufacturing consulting company that he founded in 2010.
  • Brian Parker, GeminiBio CEO and board director, stated "I am very excited to have Steven join the board and am confident that he will provide invaluable support to me and my team as we work to help our customers streamline their bioproduction workflows.
  • GeminiBio can be a valuable resource to CDMOs and manufacturers who outsource their media hydration and buffer manufacturing, helping these companies focus on their core product manufacturing."
  • I am looking forward to helping the Board and management team execute on its growth plan."

Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund

Retrieved on: 
Wednesday, January 17, 2024
House, Research, Health care, SIX Swiss Exchange, Risk, AG, Health, Capital, Growth, Harmony Row, South, Grand Canal Dock, Lux, Post office box, Prospectus, UnitedHealth Group, Drug development, Annual report, SICAV, Investment, CNMV, OpenAI, Heart failure, Portfolio, Amgen, TEL, Judgement, PwC, USD, CHF

Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund

Key Points: 
  • Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund
    Media release of January 15, 2024
    Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund
    Generative Artificial Intelligence (GenAI) is bringing about an unprecedented technological transformation.
  • “The investment approach we are taking with the Bellevue AI Health (Lux) Fund that was launched on November 30, 2023 is different.
  • Healthcare will benefit greatly from GenAI,” says Co-Portfolio Manager Stefan Blum, which explains the rationale behind the launch of Bellevue Asset Management's latest healthcare fund.
  • The IT-related risks of implementing AI in healthcare are more calculable than in other industries because healthcare is such a highly regulated market.

Cullgen Announces Additions to Board of Directors and Scientific Advisory Board

Retrieved on: 
Tuesday, January 16, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Amgen, University, DRS, GSK, Business development, Pfizer, Drug development, California Institute of Technology, Doctor of Philosophy, Therapy, AstraZeneca, Ohio State University, Storer, Inc.

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.

Key Points: 
  • Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.
  • Pan Xiaogang, currently Managing Director of AstraZeneca-CICC Fund and Business Development in AstraZeneca China, leads the investment activities in innovative medicine.
  • Xiaogang has nearly 20 years of combined experiences in research, business development and investment.
  • Pan and Storer join Cullgen in these important advisory roles.

Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

Retrieved on: 
Tuesday, January 16, 2024
JPMorgan Chase, Amgen, Research, Mitsui & Co., Airbus, AI, HSBC, Carbon, Digital, Transport, Cambridge Quantum Computing, Organization, Computational chemistry, BMW, Cryptocurrency

CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion. The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder. This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.

Key Points: 
  • CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion.
  • The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder.
  • This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.
  • This capital raise represents Quantinuum's first equity funding round since Cambridge Quantum Computing and Honeywell Quantum Solutions merged in November 2021.

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

Retrieved on: 
Wednesday, January 10, 2024
University, Amgen, Therapy, Senior management, ADC, Religious studies, MBA, Acquisition, Harvard Business School, BLA, Lundbeck, Management

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors.

Key Points: 
  • LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors.
  • Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’s Board.
  • “The Autolus Board and Management Team would like to welcome Bob Azelby to the Board of Directors.
  • He currently serves on the Board of Directors at ADC Therapeutics SA and has also served on the Board of Directors of Chinook Therapeutics Inc, Clovis Oncology Inc., Eliem Therapeutics Inc., Alder BioPharmaceuticals Inc., Cascadian Therapeutics, Inc., and Immunomedics, Inc.

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Retrieved on: 
Wednesday, January 10, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Amgen, TED, Teprotumumab, Graves' ophthalmopathy, License, Pharmaceutical industry

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.
  • Teprotumumab-trbw is known as TEPEZZA® in the United States.
  • “We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneous teprotumumab to potentially enhance the patient experience and delivery of the treatment for Thyroid Eye Disease.
  • This agreement to license XeriJect further validates the potential value of our technology to enable large molecule subcutaneous injections that provide a more patient friendly regimen that is effective, safe, and more convenient, with potential for improved adherence,” said Paul R. Edick, Chairman and CEO of Xeris.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.